Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 2026

8.12.2025 08:00:00 CET | Business Wire | Press Release

Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8^th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders.

“Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”

Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include:

Lower Limb Spasticity

IncobotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy: Evaluation of Lower Limb IncobotulinumtoxinA Efficacy (ELLIE)
Authors: Marta Banach, Iryna Makedonska, Veronika Mykhaylenko, Angelika Hanschmann, Thorin Geister, Andrzej Dekundy
Presenter: Sebastian Schröder, MD (Germany)
Location and Time: Clinical Track 1B – Thursday, 15 January 2026, 17:40 – 17:55 p.m.

Upper Limb Spasticity – Shoulder Management

Pathways for diagnosis and multimodal management, including botulinum neurotoxin therapy, in shoulder conditions following central lesions
Authors: Bo Biering-Sørensen, Carlos Cordero-García, Chris Boulias, Damon Hoad, Djamel Bensmail, Franco Molteni, François Genêt, Jörg Wissel, Philippe Marque, Steffen Berweck, Jorge Jacinto
Location and Time: Poster and Exhibit Hall, 14-17 January 2026

Cervical Dystonia

Real-world Evidence of Longevity of BoNT/A in Cervical Dystonia (RELY-CD)
Authors: Benjamin Wäschle, John Ih Lee, Tristan Kölsche, Robin Jansen, Piotr Sobolewski, Sara Sánchez Valiente, Eva López Valdés, Pablo Mir, Silvia Jesús, Elena Ojeda Lepe, Ewa Papuć, Pilar Sánchez Alonso, Gabriel Salazar, Georg Comes, Holger Stark, Philipp Albrecht
Location and Time: Poster and Exhibit Hall, 14-17 January 2026

Pain

Evaluating the efficacy and safety of IncobotulinumtoxinA in adults with moderate to severe chronic peripheral neuropathic pain - The Phase 2 PaiNT Study Design
Authors: Nadine Attal, Irena Pulte, Ilona Bicker, Ralf Baron, Nanna B. Finnerup, Thorin L. Geister, Eric Viel
Location and Time: Poster and Exhibit Hall, 14-17 January 2026

Immunogenicity and Secondary Treatment Failure

A systematic review and meta-analysis of neutralizing antibodies after treatment with abobotulinumtoxinA, incobotulinumtoxinA and onabotulinumtoxinA across multiple indications
Authors: Uwe Walter, Phillipp Albrecht, Warner Carr, Harald Hefter
Location and Time: Poster and Exhibit Hall, 14-17 January 2026
Secondary treatment failure with abobotulinumtoxinA, incobotulinumtoxinA and onabotulinumtoxinA: A systematic review and meta-analysis
Authors: Uwe Walter, Phillipp Albrecht, Warner Carr, Harald Hefter
Location and Time: Poster and Exhibit Hall, 14-17 January 2026

Toxins congress attendees can connect with Merz Therapeutics at the booth to learn more about the company, its pipeline and ongoing research.

About Merz Therapeutics

Merz Therapeutics GmbH is dedicated to delivering better outcomes for more patients. With science as its foundation and the patient experience as its focus, the company relentlessly pursues innovative treatments and partnerships to address unmet needs in movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life.

Merz Therapeutics is headquartered in Frankfurt am Main, Germany, and is active in more than 80 countries. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company with a 117-year legacy. With passion and purpose, Merz Therapeutics continues to advance care in specialty neurology in ways that benefit both patients and society.

Please visit www.merztherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251205989473/en/

Contacts

Press Contact:
Merz Therapeutics GmbH
Luke Anthony Mircea-Willats
Global Communications
luke.mirceawillats@merz.ch

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting Broadens Capabilities Through Collaboration with Acumen Learning12.3.2026 14:30:00 CET | Press Release

Andersen Consulting adds depth to its platform through a Collaboration Agreement with Acumen Learning, a U.S.-based firm specializing in business and financial acumen training for leadership development and sales performance. Founded in 2002, Acumen Learning works with Fortune 500 companies to enhance financial literacy, strategic thinking, and decision-making across all levels. Drawing from the principles in their best-selling books “Seeing the Big Picture” and “Business Acumen for Sales Success,” their programs equip leaders and teams to align decisions with corporate strategy, drive performance, and strengthen client relationships. Tailored for industries such as healthcare, energy, and technology, Acumen Learning empowers professionals to translate business knowledge into actionable impact. “At Acumen Learning, our mission is to empower individuals by creating business-savvy professionals who excel in their careers,” said CEO of Acumen Learning Kevin Cope. “Our courses pair practic

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press Release

Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and collaborations with leading pharmaceutical companies, including MSD since 2023 for MSIntuit, Waiv is establishing itself as a leader in translational medical AI. Waiv leverages a decade of Owkin's foundational medical AI research, including access to an extensive patient data net

RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press Release

RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that helps sponsors gain earlier clarity, reduce risk, and execute complex programs

Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press Release

Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cryptio was built to address this gap. The company’s data platform standardizes and reconciles both on-chain and

HyperLight Introduces 145 GHz Reference Modulators to Enable 448Gbps per Lane Datacom and 260GBaud Telecom Development12.3.2026 14:03:00 CET | Press Release

HyperLight Corporation, creator of the TFLN Chiplet™ platform, today announced the release of its 145 GHz Packaged Intensity Modulator (IM), expanding the company‘s high-speed modulator portfolio. The new device is designed for ultra-wide modulation bandwidth, high signal fidelity, and stable operation control, enabling 448 Gbps per lane intensity-modulated-direct-detection (IMDD), 260 GBaud coherent links, and broadband RF photonics systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312319685/en/ Fig. 1: HyperLight’s 145 GHz intensity modulator for 448Gbps per lane IMDD and 260GBaud coherent applications, with operational electro-optical bandwidth >145GHz, stable bias control, 0.8 mm-connector; available in O-, C-, and L-bands. As symbol rates and analog bandwidth requirements continue to rise across data center interconnects, AI-driven photonics infrastructure, and laboratory test environments, system architects in

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom